InterMune Wins EU Approval
InterMune (NASDAQ: ITMN), the Brisbane, CA-based drug developer, said today that pirfenidone (Esbriet) has been cleared by regulators for sale in the 27 countries that make up the European Union. The drug will be marketed to treat mild to moderate idiopathic pulmonary fibrosis. InterMune says it plans to start commercializing the drug in September in Germany, followed by France, Spain, Italy and the U.K. in 2012. InterMune failed to win FDA approval last May, but it rebounded in December on a positive recommendation from a European drug advisory board.